“…A number of studies have reported the association of PD‐1 inhibitors with oral lichenoid reactions (Schaberg et al, ; Shi et al, ; Sibaud et al, ), SJS (Saw et al, ), toxic epidermal necrolysis (TEN) (Nayar et al, ), bullous pemphigoid (Jour et al, ), EM (Utsunomiya et al, ), and sicca syndrome (Cappelli et al, ; Teyssonneau, Cousin, & Italiano, ; Warner et al, ). Nevertheless, further characterization of oral lesions and management outcomes warrants study.…”